Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
52
VNDA Quote, Financials, Valuation and Earnings
Last price:
$7.33
Seasonality move
:
-4.46%
Day range:
$8.06 - $8.55
52-week range:
$3.81 - $9.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.37x
P/B ratio:
1.08x
Volume:
1.8M
Avg. volume:
2.4M
1-year change:
76.08%
Market cap:
$504.7M
Revenue:
$198.8M
EPS (TTM):
-$1.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$59.3M | -- | 11.45% | -- | $13.13 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$293.6M | $0.15 | 12.96% | -83.59% | $30.47 |
|
ADMA
ADMA Biologics, Inc.
|
$139.9M | $0.20 | 18.97% | -56.04% | $25.67 |
|
ALDX
Aldeyra Therapeutics, Inc.
|
$24.3M | -$0.15 | -- | -44.74% | $9.67 |
|
EXEL
Exelixis, Inc.
|
$609.2M | $0.76 | 7.5% | 59.24% | $45.17 |
|
LLY
Eli Lilly & Co.
|
$17.8B | $7.17 | 31.31% | 54.16% | $1,098.04 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$8.54 | $13.13 | $504.7M | -- | $0.00 | 0% | 2.37x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$27.42 | $30.47 | $4.6B | 17.64x | $0.00 | 0% | 4.41x |
|
ADMA
ADMA Biologics, Inc.
|
$18.82 | $25.67 | $4.5B | 22.10x | $0.00 | 0% | 9.47x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
$4.16 | $9.67 | $250.3M | -- | $0.00 | 0% | -- |
|
EXEL
Exelixis, Inc.
|
$46.19 | $45.17 | $12.4B | 19.45x | $0.00 | 0% | 5.78x |
|
LLY
Eli Lilly & Co.
|
$1,108.09 | $1,098.04 | $991.8B | 54.80x | $1.50 | 0.54% | 17.00x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | -0.960 | 3.7% | 2.92x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.825 | 1.52% | 2.70x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -3.305 | 2.38% | 3.53x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
23.99% | 2.161 | 4.95% | 2.64x |
|
EXEL
Exelixis, Inc.
|
7.55% | 0.175 | 1.59% | 3.47x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.496 | 6.22% | 0.65x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-$63.7K | -$8M | -53.75% | -66.61% | -- | -$7M |
|
EXEL
Exelixis, Inc.
|
$579.2M | $256.4M | 28.73% | 31.26% | 42.89% | $288.8M |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
Vanda Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns VNDA or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -40.15% compared to Vanda Pharmaceuticals, Inc.'s net margin of 25.76%. Vanda Pharmaceuticals, Inc.'s return on equity of -16.55% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About VNDA or ACAD?
Vanda Pharmaceuticals, Inc. has a consensus price target of $13.13, signalling upside risk potential of 53.69%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $30.47 which suggests that it could grow by 11.14%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is VNDA or ACAD More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.604, which suggesting that the stock is 39.647% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.679, suggesting its less volatile than the S&P 500 by 32.083%.
-
Which is a Better Dividend Stock VNDA or ACAD?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNDA or ACAD?
Vanda Pharmaceuticals, Inc. quarterly revenues are $56.3M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Vanda Pharmaceuticals, Inc.'s net income of -$22.6M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 17.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 2.37x versus 4.41x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.2.37x -- $56.3M -$22.6M ACADACADIA Pharmaceuticals, Inc.4.41x 17.64x $278.6M $71.8M
-
Which has Higher Returns VNDA or ADMA?
ADMA Biologics, Inc. has a net margin of -40.15% compared to Vanda Pharmaceuticals, Inc.'s net margin of 27.14%. Vanda Pharmaceuticals, Inc.'s return on equity of -16.55% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About VNDA or ADMA?
Vanda Pharmaceuticals, Inc. has a consensus price target of $13.13, signalling upside risk potential of 53.69%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 36.38%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 ADMAADMA Biologics, Inc.3 0 0 -
Is VNDA or ADMA More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.604, which suggesting that the stock is 39.647% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.466, suggesting its less volatile than the S&P 500 by 53.393%.
-
Which is a Better Dividend Stock VNDA or ADMA?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNDA or ADMA?
Vanda Pharmaceuticals, Inc. quarterly revenues are $56.3M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Vanda Pharmaceuticals, Inc.'s net income of -$22.6M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 22.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 2.37x versus 9.47x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.2.37x -- $56.3M -$22.6M ADMAADMA Biologics, Inc.9.47x 22.10x $134.2M $36.4M
-
Which has Higher Returns VNDA or ALDX?
Aldeyra Therapeutics, Inc. has a net margin of -40.15% compared to Vanda Pharmaceuticals, Inc.'s net margin of --. Vanda Pharmaceuticals, Inc.'s return on equity of -16.55% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M -
What do Analysts Say About VNDA or ALDX?
Vanda Pharmaceuticals, Inc. has a consensus price target of $13.13, signalling upside risk potential of 53.69%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 132.37%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than Vanda Pharmaceuticals, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than Vanda Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 ALDXAldeyra Therapeutics, Inc.4 0 0 -
Is VNDA or ALDX More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.604, which suggesting that the stock is 39.647% less volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.858, suggesting its less volatile than the S&P 500 by 14.241%.
-
Which is a Better Dividend Stock VNDA or ALDX?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNDA or ALDX?
Vanda Pharmaceuticals, Inc. quarterly revenues are $56.3M, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. Vanda Pharmaceuticals, Inc.'s net income of -$22.6M is lower than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 2.37x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.2.37x -- $56.3M -$22.6M ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M
-
Which has Higher Returns VNDA or EXEL?
Exelixis, Inc. has a net margin of -40.15% compared to Vanda Pharmaceuticals, Inc.'s net margin of 32.38%. Vanda Pharmaceuticals, Inc.'s return on equity of -16.55% beat Exelixis, Inc.'s return on equity of 31.26%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M EXELExelixis, Inc.96.89% $0.70 $2.3B -
What do Analysts Say About VNDA or EXEL?
Vanda Pharmaceuticals, Inc. has a consensus price target of $13.13, signalling upside risk potential of 53.69%. On the other hand Exelixis, Inc. has an analysts' consensus of $45.17 which suggests that it could fall by -2.22%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Exelixis, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Exelixis, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 EXELExelixis, Inc.9 8 0 -
Is VNDA or EXEL More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.604, which suggesting that the stock is 39.647% less volatile than S&P 500. In comparison Exelixis, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.171%.
-
Which is a Better Dividend Stock VNDA or EXEL?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Exelixis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNDA or EXEL?
Vanda Pharmaceuticals, Inc. quarterly revenues are $56.3M, which are smaller than Exelixis, Inc. quarterly revenues of $597.8M. Vanda Pharmaceuticals, Inc.'s net income of -$22.6M is lower than Exelixis, Inc.'s net income of $193.6M. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Exelixis, Inc.'s PE ratio is 19.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 2.37x versus 5.78x for Exelixis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.2.37x -- $56.3M -$22.6M EXELExelixis, Inc.5.78x 19.45x $597.8M $193.6M
-
Which has Higher Returns VNDA or LLY?
Eli Lilly & Co. has a net margin of -40.15% compared to Vanda Pharmaceuticals, Inc.'s net margin of 31.72%. Vanda Pharmaceuticals, Inc.'s return on equity of -16.55% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About VNDA or LLY?
Vanda Pharmaceuticals, Inc. has a consensus price target of $13.13, signalling upside risk potential of 53.69%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,098.04 which suggests that it could fall by -0.91%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 LLYEli Lilly & Co.18 7 0 -
Is VNDA or LLY More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.604, which suggesting that the stock is 39.647% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.
-
Which is a Better Dividend Stock VNDA or LLY?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.54% to investors and pays a quarterly dividend of $1.50 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios VNDA or LLY?
Vanda Pharmaceuticals, Inc. quarterly revenues are $56.3M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Vanda Pharmaceuticals, Inc.'s net income of -$22.6M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 54.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 2.37x versus 17.00x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.2.37x -- $56.3M -$22.6M LLYEli Lilly & Co.17.00x 54.80x $17.6B $5.6B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
70
RGC alert for Jan 8
Regencell Bioscience Holdings Ltd. [RGC] is down 21.5% over the past day.
Buy
64
RVMD alert for Jan 8
Revolution Medicines, Inc. [RVMD] is up 4.61% over the past day.
Sell
38
CRNX alert for Jan 8
Crinetics Pharmaceuticals, Inc. [CRNX] is down 0.23% over the past day.
